ArticleMolecular biology reports2026
Analysis of CCR2 gene variants in patients with sarcoidosis using targeted next-generation sequencing: a case-control study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundSarcoidosis is a systemic granulomatous disease of unknown etiology. Genetic susceptibility and environmental factors are thought to play a role in the development of the disease. In this study, we aimed to investigate CCR2 gene variants in patients diagnosed with sarcoidosis using next-generation sequencing (NGS).
methodsA total of 50 individuals were included in the study, consisting of 31 patients followed with a diagnosis of sarcoidosis in the Department of Chest Diseases at Düzce University Faculty of Medicine and 19 controls who presented for reasons other than sarcoidosis. DNA was isolated from peripheral blood samples obtained from the participants, and CCR2 (NM_001123396.4) gene variants were analyzed using targeted next-generation sequencing.
resultsIn the study, NM_001123396.4:c.1044G>A (p.Thr348=) (rs3092960), NM_001123396.4:c.156G>T (p.Val52=) (rs3918367), NM_001123396.4:c.190G>A (p.Val64Ile) (rs1799864), and NM_001123396.4:c.780T>C (p.Asn260=) (rs1799865) variants were detected in the CCR2 gene. The statistical significance mainly resulted from the higher frequency of the NM_001123396.4:c.780T>C (p.Asn260=) (rs1799865) variant in the sarcoidosis group compared with the control group (p<0.05). Although the NM_001123396.4:c.156G>T (p.Val52=) (rs3918367) variant was detected only in the patient group, a reliable statistical inference could not be made due to the small number of cases.
conclusionsThese findings suggest that CCR2 gene variants may be associated with genetic susceptibility in the development of sarcoidosis. Further studies including larger patient series are needed to better understand the role of CCR2 polymorphisms in the etiopathogenesis of sarcoidosis.
Indexed as
Identifiers
42900239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.